Annovis_Corp_Image.png
Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio
30 janv. 2024 08h00 HE | Annovis Bio Inc.
MALVERN, Pa., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the filing...
Annovis_Corp_Image.png
Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement
24 janv. 2024 08h00 HE | Annovis Bio Inc.
MALVERN, Pa., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, has announced a...
Annovis_Corp_Image.png
Annovis Bio to Participate in the 139th Yale CEO Summit
11 déc. 2023 13h00 HE | Annovis Bio Inc.
BERWYN, Pa., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s...
Annovis_Corp_Image.png
Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease
05 déc. 2023 07h30 HE | Annovis Bio Inc.
BERWYN, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last...
Annovis_Corp_Image.png
Annovis Bio Appoints Andrew Walsh as Vice President Finance
01 déc. 2023 07h30 HE | Annovis Bio Inc.
BERWYN, Pa., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s...
Annovis_Corp_Image.png
Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections
27 nov. 2023 07h30 HE | Annovis Bio Inc.
BERWYN, Pa., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company addressing neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s...
Annovis_Corp_Image.png
Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update
08 nov. 2023 17h00 HE | Annovis Bio Inc.
BERWYN, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases,...
Annovis_Corp_Image.png
Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study
12 oct. 2023 08h02 HE | Annovis Bio Inc.
BERWYN, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today...
Annovis_Corp_Image.png
Annovis Bio to Present at the BIO CEO & Investor Digital Conference
16 févr. 2021 06h45 HE | Annovis Bio Inc.
BERWYN, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis_Corp_Image.png
Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report
17 déc. 2020 06h45 HE | Annovis Bio Inc.
BERWYN, Pa., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...